Seelos therapeutics receives fda fast track designation for intranasal racemic ketamine (sls-002)

Seelos therapeutics receives fda fast track designation for intranasal racemic ketamine (sls-002).seelos therapeutics - data from phase i study of sls-002 to evaluate pharmacokinetics, pharmacodynamics, drug-drug interactions expected in q1 2020.
SEEL Ratings Summary
SEEL Quant Ranking